In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly. As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…
Ken Keller, President & CEO, Daiichi Sankyo, Inc., and Global Head of Oncology Business on the adventure of a lifetime and how each new one shapes who he is.
Dalal Nesheiwat discusses her PharmD experience and the role of family and mentorship in her pursuit of a fulfilling career.
Our Leaders of Innovation: Mark Rutstein, MD, Senior Vice President, Global Head Oncology Clinical Development